Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerUrate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancerRasburicase (Elitek): a novel agent for tumor lysis syndrome.The tumor lysis syndromeRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutEffect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.Rasburicase: a potent uricolytic agent.Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeuticsResults of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.Management of hyperuricemia with rasburicase review.Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience.Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.Clarifying the role of rasburicase in tumor lysis syndrome.Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).Rasburicase for the treatment of tumor lysis in hematological malignancies.Drug discovery for hyperuricemia.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.Childhood acute lymphoblastic leukemia.Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome.Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.Treatment of impending tumor lysis with single-dose rasburicase.Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.Acute renal failure in cancer patients.Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer.Hemolysis and methemoglobinemia secondary to rasburicase administration.Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.Isolation, screening and production studies of uricase producing bacteria from poultry sources.Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.Recombinant production of Aspergillus Flavus uricase and investigation of its thermal stability in the presence of raffinose and lactose.Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?
P2860
Q24194387-4D19E01F-2D76-4BA6-B922-9D88D8C9F226Q24234902-6E099D17-760F-414D-B98B-89A24E014BE3Q24531989-D9CA665F-6F3D-468A-B042-A10B3329AD73Q24605151-54B501BE-16E1-47EC-B8F0-5DF3E87A2A3AQ24673444-AE224102-C990-4B57-8EF5-D31E74C60474Q33758537-6307F601-B032-4B6A-A288-591E6E78EFF1Q34588722-8DFEC6AD-0292-42B6-B894-1F4CD61DD762Q35088800-69379460-5969-4D2E-B293-7076CB77AD9FQ35204936-EBA0CA98-307F-49F5-A39A-4AC3B7AD0DE6Q35578918-0A565258-55A6-4089-8DFF-54320173DD8FQ35750976-821F2FB5-8E03-4744-9B91-34EAF1DE8566Q35967215-E9B3B338-6A25-48E5-9D33-D64E9566F22CQ36522945-D2099A7D-F02C-4BDD-8654-FA27796C4162Q36629257-EE3A68A5-BA3F-4CA8-8CA0-1BE61E03E5D1Q36693863-03C9EDA3-9B51-4319-B89F-8A07C0F60371Q37586944-0AB2FFDF-B28C-4BD2-B32F-2304D541B13FQ37978342-8853795F-E2F0-4686-82A7-3AF59EA552EBQ38089866-8C01EC02-98B9-4257-BD64-E4C4451F4369Q38921102-D9F14C04-1A30-4457-870C-AFFFA00C0ED9Q40065094-A50183A4-2C54-4C56-9F35-D54A6737FD15Q40637650-A19734A1-38B6-4201-AF40-9E377109F819Q41119377-B6E3178D-377F-4570-A5D4-E4FCFFDBB477Q44605525-7509FE9B-C9FC-407A-988A-5F27FAA4DDEBQ44619783-23661B9F-D8DA-44ED-8816-491DF8DD5F0BQ44622771-18B0B43E-FC96-4AC5-B59F-4018B4B576E5Q45128200-5A7F3123-0CA1-4B90-A995-62CDF0FDD38EQ46498125-CCFC8D26-80BD-40DA-A531-DDEA4D27AAA1Q46575274-7115D33D-24EB-4F0E-9A52-F6F0AE65DAE0Q46735562-CDD266FE-A477-46AB-93BD-7F8C170DC9C6Q46849211-828C5353-234B-4E82-A3D4-82B560D1FEE9Q46902520-1D9BCFF2-8835-4A80-9A48-7EB1E54F68D0Q46966911-8F7311D5-C3E9-430A-A0E9-117B284B6979Q48033577-5AD42DB6-672E-46A7-80CA-1072795BBEC8Q55428086-7CD03406-30C3-4E50-B923-89721A7595ABQ56968010-390ACE3B-C994-483F-B4FE-6B9E3A3EE0C5
P2860
Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Recombinant urate oxidase (ras ...... of a compassionate-use trial.
@en
type
label
Recombinant urate oxidase (ras ...... of a compassionate-use trial.
@en
prefLabel
Recombinant urate oxidase (ras ...... of a compassionate-use trial.
@en
P2093
P356
P1433
P1476
Recombinant urate oxidase (ras ...... of a compassionate-use trial.
@en
P2093
P2888
P304
P356
10.1038/SJ.LEU.2402235
P577
2001-10-01T00:00:00Z
P5875
P6179
1052377795